Methoxyetomidate
Appearance
| Clinical data | |
|---|---|
| Other names | ET-26; Moxetomidate |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C15H18N2O3 |
| Molar mass | 274.320 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Methoxyetomidate (Methoxyethyl etomidate) is an investigational anesthetic agent being developed by Jinzhou Ahon Pharmaceutical Co., Ltd. It is a short-acting intravenous anesthetic that acts as a positive allosteric modulator of GABAA receptors.[1][2][3] As of 2024, methoxyetomidate is undergoing Phase 3 clinical trials for use in anesthesia.[4][1][5][6][7][8]
References
[edit]- 1 2 "ET-26 Methoxyetomidate Hydrochloride Development Information". Synapse by Patsnap. Retrieved 2024-11-23.
- ↑ Wang B, Chen S, Yang J, Yang L, Liu J, Zhang W (2017). "ET-26 hydrochloride (ET-26 HCl) has similar hemodynamic stability to that of etomidate in normal and uncontrolled hemorrhagic shock (UHS) rats". PLOS ONE. 12 (8) e0183439. Bibcode:2017PLoSO..1283439W. doi:10.1371/journal.pone.0183439. PMC 5557577. PMID 28813523.
- ↑ Liu X, Song H, Yang J, Zhou C, Kang Y, Yang L, Liu J, Zhang W. The etomidate analog ET-26 HCl retains superior myocardial performance: Comparisons with etomidate in vivo and in vitro. PLoS One. 2018 Jan 11;13(1):e0190994. doi: 10.1371/journal.pone.0190994. PMID: 29324898Liu X, Song H, Yang J, Zhou C, Kang Y, Yang L, Liu J, Zhang W. The etomidate analog ET-26 HCl retains superior myocardial performance: Comparisons with etomidate in vivo and in vitro. PLoS One. 2018 Jan 11;13(1):e0190994. doi:10.1371/journal.pone.0190994 PMID 29324898
- ↑ "ET-26 Clinical Trials Overview". Synapse by Patsnap. Retrieved 2024-11-23.
- ↑ Valk BI, Struys MMRF. Etomidate and its Analogs: A Review of Pharmacokinetics and Pharmacodynamics. Clin Pharmacokinet. 2021 Oct;60(10):1253-1269. doi:10.1007/s40262-021-01038-6 PMID 34060021
- ↑ Philip AB, Brohan J, Goudra B. The Role of GABA Receptors in Anesthesia and Sedation: An Updated Review. CNS Drugs. 2025 Jan;39(1):39-54. doi:10.1007/s40263-024-01128-6 PMID 39465449
- ↑ Chen Y, Wu L, Lang B, Zhang W, Chen S. Recent progress in the development of etomidate analogues. Front Pharmacol. 2025 Oct 14;16:1614865. doi:10.3389/fphar.2025.1614865 PMID 41164750
- ↑ Chittoria K, Sharma A. The novel etomidate analog: A potential induction agent. Saudi J Anaesth. 2025 Oct-Dec;19(4):614-616. doi:10.4103/sja.sja_503_25 PMID 40994477